In vivo dynamics and anti-tumor effects of EpCAM-directed CAR T-cells against brain metastases from lung cancer

References

• Achrol AS, Rennert RC, Anders C, Soffietti R, Ahluwalia MS, Nayak L, Peters S, Arvold ND, Harsh GR, Steeg PS, et al. Brain metastases. Nat Rev Dis Primers. 2019;5(1):5. doi:10.1038/s41572-018-0055-y.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, Mazieres J, Kim D-W, Mok T, Polli A, et al. First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer. N Engl J Med. 2020;383(21):2018–13. doi:10.1056/NEJMoa2027187.
   PubMed Web of Science ®Google Scholar
• Karschnia P, Le Rhun E, Vogelbaum MA, et al. The evolving role of neurosurgery for central nervous system metastases in the era of personalized cancer therapy. Eur J Cancer. 2021;156:93–108. doi:10.1016/j.ejca.2021.07.032.
   PubMed Web of Science ®Google Scholar
• Goldberg SB, Schalper KA, Gettinger SN, Mahajan A, Herbst RS, Chiang AC, Lilenbaum R, Wilson FH, Omay SB, Yu JB, et al. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2020;21(5):655–663. doi:10.1016/S1470-2045(20)30111-X.
   PubMed Web of Science ®Google Scholar
• Chong EA, Ruella M, Schuster SJ. Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy. N Engl J Med. 2021;384(7):673–674. doi:10.1056/NEJMc2030164.
   PubMed Web of Science ®Google Scholar
• Karschnia P, Teske N, Thon N, Subklewe M, Tonn J-C, Dietrich J, von Baumgarten L. CAR T-Cells for Glioblastoma Current Concepts, Challenges and Future Perspectives. Neurology. 2021;97(5):218–230. doi:10.1212/WNL.0000000000012193.
   PubMed Web of Science ®Google Scholar
• Karschnia P, Blobner J, Teske N, et al. CAR T-Cells for CNS Lymphoma: driving into New Terrain? Cancers. 2021;14(1):13. doi:10.3390/cancers14010013.
   PubMedGoogle Scholar
• Sebastian M, Passlick B, Friccius-Quecke H, Jäger M, Lindhofer H, Kanniess F, Wiewrodt R, Thiel E, Buhl R, Schmittel A, et al. Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study. Cancer Immunol Immunother. 2007;56(10):1637–1644. doi:10.1007/s00262-007-0310-7.
   PubMed Web of Science ®Google Scholar
• Kim Y, Kim HS, Cui ZY, Lee H-S, Ahn JS, Park CK, Park K, Ahn M-J. Clinicopathological implications of EpCAM expression in adenocarcinoma of the lung. Anticancer Res. 2009;29:1817–1822.
   PubMed Web of Science ®Google Scholar
• Spizzo G, Fong D, Wurm M, Ensinger C, Obrist P, Hofer C, Mazzoleni G, Gastl G, Went P. EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis. J Clin Pathol. 2011;64(5):415–420. doi:10.1136/jcp.2011.090274.
   PubMed Web of Science ®Google Scholar
• Li W, Zhou Y, Wu Z, Shi Y, Tian E, Zhu Y, Wang T, Dou W, Meng X, Chen M, et al. Targeting wnt signaling in the tumor immune microenvironment to enhancing EpCAM CAR T-Cell therapy. Front Pharmacol. 2021;12:724306. doi:10.3389/fphar.2021.724306.
   PubMed Web of Science ®Google Scholar
• Zhang W, Karschnia P, von Mücke-Heim IA, Mulazzani M, Zhou X, Blobner J, Mueller N, Teske N, Dede S, Xu T, et al. In vivo two-photon characterization of tumor-associated macrophages and microglia (TAM/M) and CX3CR1 during different steps of brain metastasis formation from lung cancer. Neoplasia. 2021;23(11):1089–1100. doi:10.1016/j.neo.2021.09.001.
   PubMed Web of Science ®Google Scholar
• Karches CH, Benmebarek MR, Schmidbauer ML, Kurzay M, Klaus R, Geiger M, Rataj F, Cadilha BL, Lesch S, Heise C, et al. Bispecific antibodies enable synthetic agonistic receptor-transduced T cells for tumor immunotherapy. Clin Cancer Res. 2019;25(19):5890–5900. doi:10.1158/1078-0432.CCR-18-3927.
   PubMed Web of Science ®Google Scholar
• Lesch S, Blumenberg V, Stoiber S, Gottschlich A, Ogonek J, Cadilha BL, Dantes Z, Rataj F, Dorman K, Lutz J, et al. T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours. Nat Biomed Eng. 2021;5(11):1246–1260. doi:10.1038/s41551-021-00737-6.
   PubMed Web of Science ®Google Scholar
• Cadilha BL, Benmebarek MR, Dorman K, Oner A, Lorenzini T, Obeck H, Vänttinen M, Di Pilato M, Pruessmann JN, Stoiber S, et al. Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors. Sci Adv. 2021;7(24). doi:10.1126/sciadv.abi5781.
   PubMed Web of Science ®Google Scholar
• Rapp M, Grassmann S, Chaloupka M, Layritz P, Kruger S, Ormanns S, Rataj F, Janssen K-P, Endres S, Anz D, et al. C-C chemokine receptor type-4 transduction of T cells enhances interaction with dendritic cells, tumor infiltration and therapeutic efficacy of adoptive T cell transfer. Oncoimmunology. 2016;5(3):e1105428. doi:10.1080/2162402X.2015.1105428.
   PubMed Web of Science ®Google Scholar
• Winkler F, Kienast Y, Fuhrmann M, Von Baumgarten L, Burgold S, Mitteregger G, Kretzschmar H, Herms J. Imaging glioma cell invasion in vivo reveals mechanisms of dissemination and peritumoral angiogenesis. Glia. 2009;57(12):1306–1315. doi:10.1002/glia.20850.
   PubMed Web of Science ®Google Scholar
• Kienast Y, von Baumgarten L, Fuhrmann M, Klinkert WEF, Goldbrunner R, Herms J, Winkler F. Real-time imaging reveals the single steps of brain metastasis formation. Nat Med. 2010;16(1):116–122. doi:10.1038/nm.2072.
   PubMed Web of Science ®Google Scholar
• Bakker R, Tiesinga P, Kötter R. The scalable brain atlas: instant web-based access to public brain atlases and related content. Neuroinformatics. 2015;13(3):353–366. doi:10.1007/s12021-014-9258-x.
   PubMed Web of Science ®Google Scholar
• Boissonnas A, Fetler L, Zeelenberg IS, Hugues S, Amigorena S. In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor. J Exp Med. 2007;204(2):345–356. doi:10.1084/jem.20061890.
   PubMed Web of Science ®Google Scholar
• Mulazzani M, Fräßle SP, von Mücke-Heim I, Langer S, Zhou X, Ishikawa-Ankerhold H, Leube J, Zhang W, Dötsch S, Svec M, et al. Long-term in vivo microscopy of CAR T cell dynamics during eradication of CNS lymphoma in mice. Proc Natl Acad Sci U S A. 2019;116(48):24275–24284. doi:10.1073/pnas.1903854116.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Marchesi F, Garlanda C. Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discov. 2022;21(11):799–820. doi:10.1038/s41573-022-00520-5.
   PubMed Web of Science ®Google Scholar
• Donovan LK, Delaidelli A, Joseph SK, Bielamowicz K, Fousek K, Holgado BL, Manno A, Srikanthan D, Gad AZ, Van Ommeren R, et al. Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. Nat Med. 2020;26(5):720–731. doi:10.1038/s41591-020-0827-2.
   PubMed Web of Science ®Google Scholar
• Wang D, Starr R, Chang WC, et al. Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma. Sci Transl Med. 2020;2020:12.
   Google Scholar
• Priceman SJ, Tilakawardane D, Jeang B, et al. Regional delivery of chimeric antigen receptor-engineered t cells effectively targets HER2(+) breast cancer metastasis to the brain. Clin Cancer Res. 2018;24(1):95–105. doi:10.1158/1078-0432.CCR-17-2041.
   PubMed Web of Science ®Google Scholar
• Kaech SM, Ahmed R. Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naïve cells. Nat Immunol. 2001;2(5):415–422. doi:10.1038/87720.
   PubMed Web of Science ®Google Scholar
• Shyer JA, Flavell RA, Bailis W. Metabolic signaling in T cells. Cell Res. 2020;30(8):649–659. doi:10.1038/s41422-020-0379-5.
   PubMed Web of Science ®Google Scholar
• Brown CE, Badie B, Barish ME, Weng L, Ostberg JR, Chang W-C, Naranjo A, Starr R, Wagner J, Wright C, et al. Bioactivity and safety of IL13Rα2-Redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma. Clin Cancer Res. 2015;21(18):4062–4072. doi:10.1158/1078-0432.CCR-15-0428.
   PubMed Web of Science ®Google Scholar
• Blaeschke F, Stenger D, Apfelbeck A, Cadilha BL, Benmebarek M-R, Mahdawi J, Ortner E, Lepenies M, Habjan N, Rataj F, et al. Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins. Blood Cancer J. 2021;11(6):108. doi:10.1038/s41408-021-00499-z.
   PubMed Web of Science ®Google Scholar
• Wang X, Huynh C, Urak R, Weng L, Walter M, Lim L, Vyas V, Chang W-C, Aguilar B, Brito A, et al. The cerebroventricular environment modifies CAR T cells for potent activity against both central nervous system and systemic lymphoma. Cancer Immunol Res. 2021;9(1):75–88. doi:10.1158/2326-6066.CIR-20-0236.
   PubMed Web of Science ®Google Scholar
• Sampson JH, Choi BD, Sanchez-Perez L, Suryadevara CM, Snyder DJ, Flores CT, Schmittling RJ, Nair SK, Reap EA, Norberg PK, et al. EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin Cancer Res. 2014;20(4):972–984. doi:10.1158/1078-0432.CCR-13-0709.
   PubMed Web of Science ®Google Scholar
• Sokolov E, Karschnia P, Benjamin R, Hadden RDM, Elwes RCD, Drummond L, Amin D, Paiva V, Pennisi A, Herlopian A, et al. Language dysfunction-associated EEG findings in patients with CAR-T related neurotoxicity. BMJ Neurology Open. 2020;2(1):e000054. doi:10.1136/bmjno-2020-000054.
   PubMedGoogle Scholar
• Karschnia P, Jordan JT, Forst DA, Arrillaga-Romany IC, Batchelor TT, Baehring JM, Clement NF, Gonzalez Castro LN, Herlopian A, Maus MV, et al. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood. 2019;133(20):2212–2221. doi:10.1182/blood-2018-12-893396.
   PubMed Web of Science ®Google Scholar
• Fajgenbaum DC, June CH, Longo DL. Cytokine Storm. N Engl J Med. 2020;383(23):2255–2273. doi:10.1056/NEJMra2026131.
   PubMed Web of Science ®Google Scholar
• Rejeski K, Perez Perez A, Sesques P, Hoster E, Berger C, Jentzsch L, Mougiakakos D, Frölich L, Ackermann J, Bücklein V, et al. CAR-HEMATOTOX: a model for CAR T-cell related hematological toxicity in relapsed/refractory large B-cell lymphoma. Blood. 2021;138(24):2499–2513. doi:10.1182/blood.2020010543.
   PubMed Web of Science ®Google Scholar
• Karschnia P, Strübing F, Teske N, Blumenberg V, Bücklein VL, Schmidt C, Schöberl F, Dimitriadis K, Forbrig R, Stemmler H-J, et al. Clinicopathologic findings in fatal neurotoxicity after adoptive immunotherapy with CD19-Directed CAR T-Cells. HemaSphere. 2021;5(3):e533. doi:10.1097/HS9.0000000000000533.
   PubMed Web of Science ®Google Scholar
• Hasegawa K, Sato A, Tanimura K, Uemasu K, Hamakawa Y, Fuseya Y, Sato S, Muro S, Hirai T. Fraction of MHCII and EpCAM expression characterizes distal lung epithelial cells for alveolar type 2 cell isolation. Respir Res. 2017;18(1):150. doi:10.1186/s12931-017-0635-5.
   PubMedGoogle Scholar
• Qin D, Li D, Zhang B, Chen Y, Liao X, Li X, Alexander PB, Wang Y, Li Q-J. Potential lung attack and lethality generated by EpCAM-specific CAR-T cells in immunocompetent mouse models. Oncoimmunology. 2020;9(1):1806009. doi:10.1080/2162402X.2020.1806009.
   PubMed Web of Science ®Google Scholar
• Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, Ostberg JR, Blanchard MS, Kilpatrick J, Simpson J, et al. Regression of glioblastoma after chimeric antigen receptor T-Cell therapy. N Engl J Med. 2016;375(26):2561–2569. doi:10.1056/NEJMoa1610497.
   PubMed Web of Science ®Google Scholar
• Agliardi G, Liuzzi AR, Hotblack A, De Feo D, Núñez N, Stowe CL, Friebel E, Nannini F, Rindlisbacher L, Roberts TA, et al. Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma. Nat Commun. 2021;12(1):444. doi:10.1038/s41467-020-20599-x.
   PubMed Web of Science ®Google Scholar
• Karschnia P, Xu T, Fitzinger E, Saliger JC, Blobner J, Teske N, von Muecke-Heim I-A, Langer S, Konhäuser M, Ishikawa-Ankerhold H, et al. TAMI-02. Depletion Of Intratumoral Tumor-Associated Macrophages And Microglia (Tam/M) Improves Checkpoint-Inhibition Therapy For Brain Metastasis From Lung Cancer. Neuro-Oncology. 2021;23(Supplement_6):vi198–vi198. doi:10.1093/neuonc/noab196.786.
   Google Scholar